Tamper-resistant oxycodone tablets have no impact on overall opioid use

January 11, 2018, University of New South Wales
Tamper-resistant oxycodone tablets have no impact on overall opioid use
Credit: Shutterstock

The introduction of tamper-resistant opioid tablets does not have an effect on rates of opioid use or harms at a population level, according to a new study led by the National Drug and Alcohol Research Centre (NDARC) at UNSW Sydney.

A tamper-resistant, difficult to crush formulation of OxyContin, a strong opioid prescribed for chronic pain management, was introduced in Australia in April 2014 in response to growing concerns about its contribution to an increase in opioid use and related harms.

The National Opioid Medications Abuse Deterrence (NOMAD) study – the most comprehensive analysis of the impact of tamper-resistant opioid formulations to date – is published in The Lancet Psychiatry journal.

The study used both sales and health data across Australia, as well as survey data from a cohort of 600 people who misuse pharmaceutical opioids, to measure the new formulation's impact on opioid use and opioid-related harm as well as opioid use and tampering among high-risk populations.

While the study found that people who inject drugs were less likely to tamper with the tablets, the lack of any significant effect on opioid use or harms highlights the need for a multifaceted approach to opioid overuse.

"Although the introduction of this tamper-resistant formulation resulted in less use of that particular opioid among people who inject drugs, its introduction must be considered as part of a multifaceted response," says NDARC's Dr. Briony Larance.

"This includes increasing the availability of non-medication approaches to chronic pain, good clinical practice in long-term opioid treatment, and harm reduction among people who use opioids outside the recommendations of their prescriber.

"Approximately 2.9 million Australians were prescribed an opioid in 2014, compared with an estimated 93,000 people who injected drugs. As a population-wide strategy to reduce harm of overuse or overprescription of opioids, the introduction of tamper-resistant formulations alone will not be sufficient to affect these outcomes," she says.

The in the USA is widely documented and similar problems in Australia are emerging, with opioid use in 2012 15 times that reported in 1992. Pharmaceutical opioids cause more than 70% of opioid overdose deaths in Australia – similar rates to the USA.

In the USA, oxycodone was developed in a tamper-resistant formulation, making it harder to crush or dissolve the tablets. Early studies suggested the tamper-resistant formulations were associated with reduced recreational use, poisonings and sales, and increased heroin use and harm.

The NOMAD study analysed a total of 17 data sources including opioid sales data, multiple health datasets, annual surveys of people who inject drugs, and a cohort of 606 people who reported tampering with opioids before and after the introduction of tamper-resistant tablets. Data from three Australian states – New South Wales, South Australia and Tasmania – were included in the study.

The introduction of tamper-resistant oxycodone was associated with a reduction in use among the cohort of people who reported tampering with the tablets to inject opioids, and there was no evidence that this cohort of people switched to other opioids.

At a population level, the introduction of tamper-resistant oxycodone was associated with reduced sales of higher strength controlled-release oxycodone, but increased sales of lower strength oxycodone formulations. Additionally, there was almost no effect on the introduction of the tamper-resistant tablets at the population level. Opioid use continued to increase at a similar rate before and after the introduction of tamper-resistant tablets.

There was no effect (positive or negative) on any population-level rates of harms, such as hospital admissions, emergency department presentations or ambulance overdoses.

The authors note that some of the datasets lacked specificity about which type of opioid was being used, which may have affected the results, but point to the strength of the study which lies in the use of multiple datasets.

In a separate editorial published in the same journal, Dr. Nabarun Dasgupta of University of North Carolina writes: "The NOMAD study provides the most complete and compelling evaluation of replacing a CR analgesic with a tamper resistant formulation of controlled release oxycodone."

Explore further: Tamper-resistant opioids will not solve opioid addiction problem

More information: Briony Larance et al. The effect of a potentially tamper-resistant oxycodone formulation on opioid use and harm: main findings of the National Opioid Medications Abuse Deterrence (NOMAD) study, The Lancet Psychiatry (2018). DOI: 10.1016/S2215-0366(18)30003-8

Related Stories

Tamper-resistant opioids will not solve opioid addiction problem

June 29, 2015
Tamper-resistant formulations of drugs will not solve the problems of opioid addiction and overdose, argues a commentary in CMAJ (Canadian Medical Association Journal).

Gabapentin co-use may increase risk of fatal opioid overdose

October 3, 2017
Co-prescription of the anticonvulsant gabapentin is associated with an increased risk of opioid-related death in people who are prescribed opioid painkillers, according to a new study published in PLOS Medicine.

CDC launches opioid campaign in hard-hit states

September 26, 2017
(HealthDay)—The U. S. Centers for Disease Control and Prevention has launched a campaign to reduce overdose deaths from prescription opioid painkillers.

Bulk of opioid use in the U.S. concentrated among 10 percent of patients

September 11, 2017
A small proportion (10 percent) of opioid users account for the vast majority of opioid use in the United States. These findings suggest that efforts to reduce prescription opioid abuse should focus on the top users, rather ...

Strategies to combat the opioid epidemic

November 15, 2017
The opioid epidemic is ravaging lives and tearing families apart. Overdose deaths from heroin, fentanyl and misused prescription painkillers have tripled in the past 15 years. Chemical & Engineering News, the weekly newsmagazine ...

More Australians dying of accidental overdose of pharmaceutical opioids

July 24, 2017
In a reversal of the heroin epidemic of the late 90s and early 2000s, older Australians aged 35 to 54 are now more likely to die from an opioid overdose, a new report reveals.

Recommended for you

Imagining a positive outcome biases subsequent memories

April 24, 2018
Imagining that a future event will go well may lead you to remember it more positively after it's over, according to findings from research published in Psychological Science, a journal of the Association for Psychological ...

Depressed, inactive and out of work—study reveals lives of lonely young adults

April 24, 2018
New research from King's College London shows that lonely young adults are more likely to experience mental health problems and more likely to be out of work than their peers. The study, published today in Psychological Medicine, ...

Sense of control and meaning helps protect women from anxiety

April 24, 2018
People who feel in control of their lives and who find purpose and meaning in life are less likely to have anxiety disorders even when going through the toughest times, according to a study led by the University of Cambridge.

Researchers identify brain mechanism linking PTSD and opioid addiction

April 23, 2018
Researchers at Western University have shown that the recall of traumatic memories enhances the rewarding effects of morphine, shedding light on the neurobiological link between post-traumatic stress disorder (PTSD) and opioid ...

Scientific guidelines for using cannabis to treat stress, anxiety and depression

April 19, 2018
In a first-of-a-kind study, Washington State University scientists examined how peoples' self-reported levels of stress, anxiety and depression were affected by smoking different strains and quantities of cannabis at home.

Neuroscientists use magnetic stimulation to amplify PTSD therapy

April 19, 2018
Researchers from The University of Texas at Dallas have found that a standard therapy for post-traumatic stress disorder (PTSD) is more effective when paired with transcranial magnetic stimulation of the brain.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.